A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data.

Fiche publication

Date publication

août 2025

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HARLE Alexandre

Tous les auteurs :
Bourien H, Adhoute X, Campillo-Gimenez B, Bouattour M, Assenat E, Nahon P, Launay S, Oberti F, Saviano A, Decaens T, Merle P, Harlé A, Lecomte T, Ternant D, Monard L, Pezzella V, Blanc JF, Edeline J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40752979

Résumé

Hepatocellular carcinoma (HCC) frequently develops in underlying cirrhosis. Liver dysfunction impacts survival and may influence treatment results. About a quarter of patients with advanced HCC present with Child-Pugh B liver functions. All recent phase 3 trials validating standard of care limited inclusion to patients with Child-Pugh A liver function. Results of immunotherapy is less described in patients with altered liver function. We previously showed that the ALBI grade might be able to better select patients with Child-Pugh B liver functions who could benefit from sorafenib. Single-agent anti-PD-(L)1 antibodies might have a more favorable safety profile than standard of care combinations.